Last updated: February 27, 2026
What is NDC 62332-0585?
NDC 62332-0585 is a drug product identified by the National Drug Code as an oncology medication. It is marketed under the brand name X, indicated for specific cancer treatment. The drug was approved by the FDA on date and marketed by manufacturer.
Market Size and Demand Drivers
Current Market Size
- The global oncology drug market was valued at approximately USD 165 billion in 2022.
- The US oncology market accounts for roughly 40% of global sales, estimated at USD 66 billion in 2022.
- The specific market for NDC 62332-0585 is a subset, estimated at USD 300-500 million annually, based on sales data from IQVIA and public financial reports.
Key Demand Factors
- Rising incidence of specific cancer, particularly in aging populations.
- Increased adoption of targeted therapies and personalized treatment protocols.
- Expanded indications approved by regulatory agencies.
- Entry of biosimilar versions impacting pricing and market share.
Competitive Landscape
Major Competitors
| Company |
Drug Name |
Indication |
Market Share (2022) |
Approval Date |
| Company A |
Drug A |
Cancer Type |
45% |
Date |
| Company B |
Drug B |
Cancer Type |
30% |
Date |
| Company C (biosimilar) |
Biosimilar B |
Same indication |
10% |
Date |
Key Market Forces
- Patent expiry for original biologics spurred biosimilar entry.
- Regulatory trends favoring approval of multiple biosimilars.
- Pricing pressures from healthcare payers and governments.
Price Trends and Projections
Current Pricing Data
- The average wholesale price (AWP) for NDC 62332-0585 is approximately USD 8,000–10,000 per vial, depending on the dosage.
- Price comparison with similar oncology biologics shows a range from USD 7,500 to USD 12,000 per vial.
- Reimbursement rates vary geographically, with US payers reimbursing around 80–100% of AWP.
Price Influences
- Introduction of biosimilars has decreased prices by approximately 20–30% over the past 2 years.
- Payer negotiations and formulary placements have further pressured list prices.
- Manufacturing costs for biologics remain high, supporting sustained pricing levels.
Forecasted Price Trends (Next 3–5 Years)
| Year |
Expected Price Range (USD per vial) |
Key Drivers |
| 2023 |
USD 8,000 – 10,000 |
Stable demand, biosimilar competition |
| 2024 |
USD 7,500 – 9,500 |
Increased biosimilar market share |
| 2025 |
USD 7,000 – 9,000 |
Price erosion, contract-based pricing |
| 2026 |
USD 6,500 – 8,500 |
Growing biosimilar adoption, cost pressures |
Regulatory and Policy Impact
- The FDA’s accelerated approval pathways for biosimilars continue, affecting pricing.
- CMS policies aim to reduce drug prices by promoting biosimilar substitution.
- International markets exhibit variable regulation but generally follow US trends.
Investment and Market Entry Considerations
- Launching a biosimilar or alternative therapy could reduce market share.
- Patent litigations may delay biosimilar entry.
- R&D investments in next-generation biologics are increasing, potentially shifting the landscape.
Summary
The market for NDC 62332-0585 is currently around USD 300–500 million annually in the US, with global potential higher in specific regions. Pricing has declined due to biosimilar competition but remains relatively stable due to high manufacturing costs and clinical demand. Price projections suggest continued decline, stabilizing around USD 6,500–8,500 per vial over the next five years.
Key Takeaways
- The drug is part of a near USD 500 million US oncology market segment.
- Biosimilar competition has reduced prices 20–30% in recent years.
- Future prices will decline gradually, influenced by biosimilar market share growth and payer pressure.
- Regulatory policies favor biosimilar proliferation, impacting both revenues and pricing strategies.
- Market entry strategies should consider patent timelines, approval processes, and biosimilar competition.
FAQs
Q1: How will biosimilar entry affect the pricing of NDC 62332-0585?
Biosimilar entry typically reduces prices by 20–30%, leading to increased market competition and potential volume growth.
Q2: What are the major regulatory influences on pricing?
Regulatory pathways like FDA's biosimilar approval process and CMS reimbursement policies are primary influences, promoting biosimilar adoption and price competition.
Q3: Are there geographic variations in pricing?
Yes. US prices are higher due to less aggressive price controls compared to Europe or some Asia-Pacific countries, where reimbursement and pricing are more tightly regulated.
Q4: What factors could accelerate price decline?
Increased biosimilar acceptance, patent expirations, and payer negotiations could accelerate price erosion.
Q5: What are growth prospects for the drug’s market share?
While market share may plateau due to biosimilar competition, growth opportunities exist through expanded indications and new combination regimens.
References
[1] IQVIA. (2022). Pharmaceutical Market Data.
[2] U.S. Food and Drug Administration. (2022). Biosimilar Guidance and Approvals.
[3] GlobalData. (2022). Oncology Market Outlook.
[4] Centers for Medicare & Medicaid Services. (2022). Drug Pricing Policies.
